Zealand Pharma A/S (ZLDPF) to Release Earnings on Thursday

Zealand Pharma A/S (OTCMKTS:ZLDPF) is expected to be posting its results before the market opens on Thursday, February 19th. Analysts expect Zealand Pharma A/S to post earnings of ($1.34) per share for the quarter.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.21. The firm had revenue of $7.76 million for the quarter, compared to analyst estimates of $4.54 million. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%. On average, analysts expect Zealand Pharma A/S to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Zealand Pharma A/S Stock Performance

OTCMKTS:ZLDPF opened at $63.84 on Thursday. The business has a 50 day moving average of $70.67 and a 200 day moving average of $70.18. The company has a market capitalization of $4.53 billion, a price-to-earnings ratio of 4.59 and a beta of 0.72. Zealand Pharma A/S has a 1-year low of $49.98 and a 1-year high of $108.30. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ZLDPF shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Five research analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.